Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
IPO Year:
Exchange: NASDAQ
Website: akaritx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/18/2025 | $5.00 | Buy | Maxim Group |
Fastest customizable press release news feed in the world
BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Tuesday, August 19, 2025 at 2:00 PM ET Presenter: Abizer Gaslightwala, President and Chief Executive Officer of AkariRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed
Watch the "What This Means" video here BOSTON and LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Abizer Gaslightwala, President and CEO of Akari Therapeutics participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr. Gaslightwala discussed its novel spliceosome modulator payload, PH1, and the Company's ongoing efforts to build on key data for its spliceosome modulator payload with further research ongoing on how the payload can also disrupt key drivers responsible for c
PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of ADCs using PH1 payload across both Trop2 and an undisclosed target Emerging new preclinical data on impact of PH1 payload against a key oncogenic driver is expected before year-end BOSTON and LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today reiterated its commitment to ongoing research to better understand the multiple effects of its novel spliceosome modulator,
BOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. As part of the event, Mr. Gaslightwala dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on virtualinvestor
Access the "What This Means" segment here BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced it recently participated in a Virtual Investor "What This Means" segment. For the segment, Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed the Company's recently issued India Patent No. 562,919 titled, "Thailanstatin Analogs," covering claims for its potent immuno-oncology PH1 payload, proprietary non-cleavable and cleavable linkers and ADC technology which has applications across var
Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms India represents a key territory with a rapidly growing incidence rate of cancer cases, projected to increase to 2.08 million by 20401 BOSTON and LONDON, June 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced the Intellectual Property India (IPI) has issued Patent No. 562,919 titled, "Thailanstatin Analogs". The issued patent covers claims for t
Access the video here BOSTON and LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the release of a "Meet the Team" video featuring newly appointed Mark F. Kubik, Head of Business Development – Oncology. The video is now available on the Presentations page under the Investors section of the Company's website (www.akaritx.com). About Akari Therapeutics Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform,
BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025 at 2:00 PM ET. Conference Details: Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar Date/Time: Thursday, May 29th at 2:20 PM ET Presenter: Abizer Gaslightwala, Director, President and CEORegistration Link: HERE About Webull Financial Webull Financial is a
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member. We look forward to following her vision and continued leadership as we
Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with deep oncology experience by appointing new Head of Business Development - Oncology BOSTON and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update. "We remain laser focused on becoming a key player in the ADC space and advancing our novel ADC platform built around i
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Maxim Group initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $5.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
8-K - Akari Therapeutics Plc (0001541157) (Filer)
10-Q - Akari Therapeutics Plc (0001541157) (Filer)
EFFECT - Akari Therapeutics Plc (0001541157) (Filer)
S-8 - Akari Therapeutics Plc (0001541157) (Filer)
S-3 - Akari Therapeutics Plc (0001541157) (Filer)
8-K - Akari Therapeutics Plc (0001541157) (Filer)
DEF 14A - Akari Therapeutics Plc (0001541157) (Filer)
PRE 14A - Akari Therapeutics Plc (0001541157) (Filer)
8-K - Akari Therapeutics Plc (0001541157) (Filer)
EFFECT - Akari Therapeutics Plc (0001541157) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
This live feed shows all institutional transactions in real time.
SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13G/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13G/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)
Live Leadership Updates
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member. We look forward to following her vision and continued leadership as we
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discovery to pre-clinical/clinical stage 25+ year-career experience bolsters Company's efforts to address growing, high-value ADC market and maximize opportunities for non-dilutive capital BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the appointment of Mark F. Kubik as Head of Business Development
Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid tumors Platform technology to fuel pipeline with ability to generate novel ADC candidates across a range of solid/hematological cancers Leveraging opportunities for non-dilutive capital through partnering of legacy pipeline Cash on hand expected to be sufficient to fund planned operations into September 2025 BOSTON and LONDON, April 16, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-fun
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B Held several executive leadership roles at Amgen, Pfizer, and Johnson & Johnson across multiple brands including Kyprolis®, Vectibix®, Neulasta®, XGEVA®, Repatha®, and ELIQUIS® Current President and CEO, Samir R. Patel, M.D., to remain as a member of the Company's Board of Directors BOSTON and LONDON, March 20, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX) ("Akari" or the "Company"), a biotechnology company developing next-generation preci
Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) today announced the appointment of Samir R. Patel, M.D., as Chief Executive Officer, effective December 16, 2024. Dr. Patel has served as interim Chief Executive Officer since May 2024. Additionally, the Company announced it has appointed Abizer Gaslightwala to its Board of Directors, effective December 16, 2024. Michael Grissinger, a member of the Board of Directors, provided notice of his resignation on December 16, 2024. "Since beginning my role as interim CEO in May 2024, we ha
BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck is a seasoned executive with over 20 years of experience in the biotechnology industry, finance, capital markets and M&A transactions, as well as clinical and commercial product development and regulatory filings in the U.S. and Europe. "We are pleased with the continued evolution and progress made across multiple fronts. We believe that adding expertise to our leadership team is a key component of ensuring continued progress and importantly our ability to build upon momentu
BOSTON and LONDON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the appointment of Rob Bazemore, experienced life sciences leader, to the Akari Board of Directors effective September 17, 2024. "I am very honored to have the opportunity to work with this distinguished board of directors to advance the portfolio opportunities," said Mr. Bazemore. "Focusing on Akari's novel lead asset, nomacopan, as well as Peak's innovative antibody-drug-conjugate (ADC) platform in oncology, has the opportunity to bring significant value both for patients and fo
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Existing Investors Support the Company with Issuance of $1 Million in Unsecured Convertible Notes Secured $7.6 Million in Upsized Financing Round Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy BOSTON and LONDON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inf
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Implementation of Restructuring Plan to Reduce Operating Costs Existing Investors Support the Company with Issuance of $1 million in Unsecured Convertible Notes BOSTON and LONDON, May 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the first quarter
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO. Rachelle Jacques will step down as Akari's Chief Executive Officer effective today. Melissa Bradford-Klug will step down as Akari's Chief Operating Officer effective today. In connection with Ms. Jacques' departure, Akari's board of directors (the "Board") has appointed Dr. Patel as Interim Chief Executive Officer. Dr. Patel has served as a member of the Board sinc
Live finance-specific insights
BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support. "I am thrilled to announce this
BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the General Meeting to be held in relation to the merger. The General Meeting will be held at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London. "I am so excited to be
Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders. Dr. Patel will be compen
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $7.6 million in gross proceeds from both new and existing investors. "We are pleased to announce this financing for Akari Therapeutics," said Samir R. Patel, MD, Interim President and CEO of Akari Therapeutics. "The overwhelming interest from investors allowed the company to upsize the transaction to $7.6 million and highlights the excitement surrou
Prioritization of Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic diseaseAkari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX, "Akari"))) and Peak Bio Inc. (OTC:PKBO, "Peak"))) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak's ADC (antibody drug conjugate) platform technology and Akari's PAS-nomacopan Geographic Atrophy (GA) program. P
BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. (OTC:PKBO), a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX. Following closing, the company will have an expanded pipeline that contains multiple compelling assets span
BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. (OTC:PKBO), a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX. Following closing, the company will have an expanded pipeline that contains multiple compelling assets span
Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP).Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) open for enrollment.Evaluating the potential for long-acting PAS-nomacopan as a treatment for dry age-related macular degeneration (AMD).Collaborating with clinical partners to explore potential for treating exacerbations in severe lung diseases where inhaled nomacopan can be potentially delivered directly to the lung.Active pipeline exploring treatment of head trauma with nomacopan and the development of votucalis, a new anti-histamine biopharmaceutical with a similar structure to